Impact Biomedical Inc (NYSE American: IBO) is a pre-revenue biomedical company that develops patented compounds targeting antimicrobial, anti-inflammatory, and metabolic disease applications. The company holds intellectual property in two primary technology platforms: Laetose, a patented sugar substitute combining one or more sugars with myo-inositol that may reduce sugar consumption by approximately 30% and lower glycemic load, and Functional Fragrance Formulation (3F), a suite of botanical-based compounds with potential applications as antibacterial, antiviral, and insect-repellent agents. IBO has not generated product revenue from these platforms as of FY2025 and funds operations through parent company capital and external financing. The company is actively seeking commercialization partners for both platforms. Total costs and expenses were $4.3M in FY2025, down from $28.8M in FY2024, which included a $25.1M goodwill impairment charge. IBO was incorporated in Nevada in 2018 and owns majority stakes in two subsidiaries: Global Biomedical Inc (90.9%) and Sweet Sense Inc (95.5%).

Revenue model

IBO had no disclosed product revenue in FY2025 or FY2024. The company reported $424,000 in cost of revenue for FY2025 with no corresponding revenue line disclosed in the filing excerpts. Operations are funded through parent company capital injections and debt. The intended future revenue model is licensing and commercialization partnerships for the Laetose and 3F technology platforms.

Products and services

Laetose: a patented formulation combining one or more sugars with myo-inositol, with a U.S. composition patent allowed in 2024 and European patent allowance disclosed in the FY2025 filing; designed for use as a dietary supplement or biopharmaceutical targeting inflammatory and metabolic diseases including diabetes. Functional Fragrance Formulation (3F): a suite of botanical compounds including terpenes with U.S. patent allowances for infectious disease applications (antibacterial, antiviral against E. coli, MRSA, influenza, rhinovirus, M. tuberculosis) and European allowance as a natural insect repellent; development partnership in place with Chemia Corporation (St. Louis, MO).

Customers and end markets

No commercial customers disclosed in the filing excerpts. Target end markets include consumer-packaged goods (dietary supplements, insect repellents, shampoos, detergents) and biopharmaceuticals (anti-inflammatory, metabolic disease, infectious disease treatments). Commercialization in both segments is dependent on securing development and distribution partners.

Value-chain role

Early-stage IP developer and licensor. IBO originates and patents biomedical formulations, then seeks third-party partners for clinical development, manufacturing, and commercialization. The company does not manufacture or distribute products directly as of the FY2025 10-K filing.

Geographic exposure

Incorporated in Nevada. Patent protection sought in the United States and internationally, with specific European allowances noted for both Laetose and 3F platforms as of the FY2025 filing. No geographic revenue breakdown disclosed.

Source: SEC 10-K, filed 2026-03-11

Industry: Pharmaceutical Preparations